Taconic Biosciences Secures CRISPR License From ERS Genomics – GlobeNewswire (press release)
|
Taconic Biosciences Secures CRISPR License From ERS Genomics
GlobeNewswire (press release) Under the agreement, Taconic receives a worldwide non-exclusive license to the CRISPR-Cas9 patents often referred to as the “UC Berkeley patent.” ERS Genomics founder, Emmanuelle Charpentier, is a co-inventor of the CRISPR-Cas9 technology. |
|
Stem cells yield nature’s blueprint for body’s vasculature …
Science Daily The developmental pathway that gives rise to the different types of cells that make up human vasculature has now been identified by a team of researchers. |
Genetic Engineering & Biotechnology News |
Crack in CRISPR Facade after Unanticipated In Vivo Mutations Arise
Genetic Engineering & Biotechnology News The CRISPR-Cas9 genome editing technique set the molecular biology field ablaze when its game-changing potential was realized only a few short years ago. In the time since the wildfire of excitement and hope has spread to almost every life science … CRISPR Gene-Editing Can Cause Hundreds of Unexpected MutationsScienceAlert CRISPR causes many unwanted mutations, small study suggestsNew Scientist Side effects of CRISPR lead to hundreds of unintended mutationsSiliconrepublic.com Cosmos –New Atlas –Economic Times all 16 news articles » |
|
Targeted Immunotherapies and Gene Therapies to Unlock New Growth Opportunities in Alzheimer’s and Parkinson’s …
PR Newswire (press release) Already, several companies are advancing clinical studies for new transformational therapies for Alzheimer’s disease (AD) and Parkinson’s disease (PD). Targeted immunotherapies and gene therapies will not only play a larger role in the effective … |
Lymphoma News Today |
FDA to Review Kite’s Application for CAR T-Cell Therapy to Treat Aggressive Non-Hodgkin’s Lymphoma
Lymphoma News Today Axicabtagene ciloleucel is a CAR (chimeric antigen receptor) T–cell therapy that removes the patient’s own T–cells and genetically engineers them to express a receptor that recognizes the CD19 protein, found at the surface of most lymphoma cells. Kite Pharma Inc Receives a Buy from FBR CapitalAnalyst Ratings |